CSBR
Champions Oncology Inc
5.00$
-5.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -52.0% | +38.7% | +0.8% | +39.5% | +84.2% | +33.0% | +28.2% | -3.0% | -23.8% | +23.8% | -16.6% | |
| – | -59.7% | +35.2% | -13.8% | +56.6% | +70.4% | -6.4% | +55.7% | -1.1% | -29.9% | +64.0% | -14.1% | |
| – | -72.4% | +27.5% | -74.0% | +278.2% | +157.7% | -43.8% | +92.2% | +12.3% | -74.1% | +273.8% | -50.2% | |
| – | -72.4% | +27.5% | -74.0% | +278.2% | +157.7% | -43.8% | +92.2% | +12.3% | -74.1% | +273.8% | -50.2% | |
| – | +23.8% | +73.3% | +72.3% | +11.7% | +9.0% | +46.5% | +36.2% | -15.8% | +18.9% | +17.9% | +17.3% | |
| – | – | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | +0.0% | – | – | |
| – | +36.7% | +96.8% | +71.3% | +22.2% | +166.7% | +115.2% | +5.2% | -5.6% | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | -49.9% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | +0.0% | +0.0% | +0.0% | – | – | – | – | – | – | – | – | |
| – | +38.9% | +37.4% | +6.5% | +11.4% | +73.4% | +28.8% | +30.3% | +12.9% | -5.5% | +1.9% | -19.8% | |
| – | +39.8% | +40.4% | +0.5% | +7.3% | +53.3% | -9.0% | +56.1% | +24.3% | -0.9% | +10.7% | -16.5% | |
| – | – | +4.2% | +16.0% | -44.8% | +3,825.0% | +30.3% | +28.9% | +14.6% | +10.7% | +10.0% | +3.3% | |
| – | +34.1% | -2.3% | +16.3% | +30.3% | +11.9% | -39.7% | +51.4% | +86.0% | +8.7% | -26.8% | +62.5% | |
| – | -35.2% | -35.6% | -57.9% | – | – | – | – | – | – | – | – | |
| – | -97.0% | +68.1% | -106.3% | – | +127.8% | +45.7% | +22.5% | -49.0% | -141.0% | – | +4.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +26.2% | +0.2% | +28.1% | -16.0% | +23.1% | -2.8% | -4.4% | +0.0% | +5.3% | -3.0% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.